Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1997 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (6890)	11/12/1997 9:17:00 PM
From: Pancho Villa	Respond to of 9285

Dale: RE: MRVT If BS bellow has any real basis to it we may be in trouble! Will investigate: "Ellis believes that combined with strong clinical data, lack of significant side effects and initial cancer focus minimizes FDA risk for the company and the investor. In 1998 the company expects to complete Phase III trials for metastatic breast cancer, Phase II/III for ARMD, Phase I/II for Psoriasis in addition to three NDA filings for cancer/dermatology indications. Ellis believes that completing these near-term milestones will drive the stock considerably. Ellis is publishing EPS estimates of $0.21 for 2000 and $6.63 for 2001" (taken from R&S basis to grant a buy rating) Pancho